FIG. 1

Pure tumor cell culture in flasks
Interferon-gamma treatment for 72 hours
Floating non-autophagic, apoptotic cells
Adherent autophagic, non-apoptotic cells
Tissue culture flask surface
Detached non-autophagic, apoptotic cell
Attached autophagic,non-apoptotic cell
Major histocompatibility complex II-over expressed in autophagic cells
Phosphatidylserine-apoptotic marker

FIG.2A



A
7-AAD-/Annexin-V+(Dying)
7-AAD-/Annexin-V-(Alive)
7-AAD+/Annexin-V+(Dead)
7-AAD+/Annexin-V-(Necrotic)
Percent
100
80
60
40
20
0
IFN-γ
-
+
-
+
-
+
-
+
2046
2270
2028
2020

FIG.2B



B
2046
2270
2028
2020
- + - + - + - +
γIFN
Hsp-60
0.99 0.89 0.96 1.01
Hsp-70
1.26 0.77 1.74 1.28
Hsp-90
0.86 0.50 0.73 1.34
Calreticulin
0.80 1.17 1.44 0.44
HMGB-1
0.84 0.95 2.85 278.0
GADPH

FIG.2C



C
2046
2270
2028
2020
- + - + - + - +
γIFN
ICAM-1
3.55
2.35
2.64
4.90
Mel-4
0.50
0.20
0.34
0.94
Mart-1
0.55
0.25
0.52
0.44
Tyrosinase
0.27
0.86
0.59
1.17
GAPDH

FIG.2D



D
Mean Fluorescence Intensity
6000
5000
4000
3000
2000
1000
0
195 +/- 86
671 +/- 124
77 +/- 199
376 +/- 229
IFN-γ
—
+
—
+
MHC Class I
MHC Class II

FIG.3A




FIG.3B



Percent MHC Class II positive
100
80
60
40
20
0
DC+TC
DC+IFN-γ TC
Isotype
CD80
CD83
CD86

FIG.4A




FIG.4B




FIG.5A




FIG.5B




FIG.5C




FIG.6A



A
5% FBS
IFN-γ Adherent Cells
IFN-γ Floating Cells
Serum Free
7-AAD
Annexin-V

FIG.6B

B




5% FBS
IFN-γ Adh.
IFN-γ Flts.
SF
Counts
0
20
40
60
80
100
10^0
10^1
10^2
10^3
10^4
Autophagy Dye

FIG.6C


2.5
2.0
1.5
1.0
0.5
0
Fold Change
IFN-γ Adherent Cells
IFN-γ Floating Cells
Serum Free




FIG.7A

FIG.7B




FIG.8





FIG.9


Mean Fluorescence Intensity
800
700
600
500
400
300
200
100
0
Non-apoptotic/MHC II+ pre-IFNg
Apoptotic/MHC II+ pre-IFNg
Non-apoptotic/MHC II+ post IFNg
Apoptotic/MHC II+ post IFNg



Fold change MHC II
16
12
8
4
0
5
10
15
20
25
30
35
40
% Annexin-V Positive

FIG. 10

FIG.11




Progression Free Survival
IFN-γ resistant
IFN-γ sensitive
Proportion
1.0
0.8
0.6
0.4
0.2
p = 0.003
0
6
12
18
24
30
36
42
48
54
60
Months

FIG.12


Overall Survival
1.0
0.8
0.6
0.4
0.2
Proportion
p = 0.002
0
6
12
18
24
30
36
42
48
54
60
Months



Superimposed survival curves from 3 trials
of patient-specific vaccines
DC54
TC74
TC24
DC18
Percent Surviving
100
90
80
70
60
50
40
30
20
10
0
0
6
12
18
24
30
36
42
48
54
60
66
72
Months

FIG. 13



Superimposed survival curves from 3 trials of patient-specific active specific immunotherapy
DC-TC-54
TC-74
TC-24
DC-TC-18
Percent Surviving
100
90
80
70
60
50
40
30
20
10
0
0
6
12
18
24
30
36
42
48
54
60
66
72
Months

Fig. 14